Effect of 3,4-diaminopyridine at the murine neuromuscular junction

被引:7
|
作者
Ng, Fiona [1 ]
Lee, Diana C. [1 ]
Schrumpf, Leah A. [1 ]
Mazurek, Mary E. [1 ]
Lee, Victoria [1 ]
Gill, Sharleen K. [1 ]
Maselli, Ricardo A. [1 ]
机构
[1] Univ Calif Davis, Sch Med, Dept Neurol, Davis, CA 95616 USA
关键词
3,4-diaminopyridine; Lambert-Eaton myasthenic syndrome; congenital myasthenic syndromes; neuromuscular junction; quantal release; endplate potential; CONGENITAL MYASTHENIC SYNDROME; MUTATIONS; TRANSMISSION; MUSK; 4-AMINOPYRIDINE; PHENOTYPES; ANTIBODY; RELEASE; AGRIN; FROG;
D O I
10.1002/mus.25208
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: We investigated the effects of 3,4-diaminopyridine (3,4-DAP) and its acetylated metabolite, N-(4-amino-pyridin-3-yl) acetamide (3-Ac), at the mammalian neuromuscular junction. Methods: Quantal release of acetylcholine was studied in diaphragm muscles of mice, using in vitro intracellular microelectrode recordings. Results: Under conditions of low probability of release, 3,4-DAP produced a 1,000% increase in quantal release, but 3-Ac had no effect. Under conditions of normal probability of release, the effect of 3,4-DAP was modest and limited by concurrent depletion of synaptic vesicles, especially with high concentrations of 3,4-DAP and high frequencies of nerve stimulation. Conclusions: These findings predict 3,4-DAP is most effective in conditions with low probability of quantal release, such as Lambert-Eaton myasthenic syndrome. A beneficial effect is also expected in disorders of neuromuscular transmission in which the effect of 3,4-DAP on quantal release is not limited by depletion of synaptic vesicles, such as postsynaptic congenital myasthenic syndromes. Muscle Nerve, 2016 Muscle Nerve55: 223-231, 2017
引用
收藏
页码:223 / 231
页数:9
相关论文
共 50 条
  • [1] Pharmacokinetics and tissue distribution of 3,4-diaminopyridine in rats
    Ishida, Natsuko
    Kondo, Yuya
    Chikano, Yuri
    Kobayashi-Nakade, Erina
    Suga, Yukio
    Ishizaki, Junko
    Komai, Kiyonobu
    Matsushita, Ryo
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2019, 40 (08) : 294 - 301
  • [2] 3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis
    Mori, Shuuichi
    Kishi, Masahiko
    Kubo, Sachiho
    Akiyoshi, Takuyu
    Yamada, Shigeru
    Miyazaki, Tsuyoshi
    Konishi, Tetsuro
    Maruyama, Naoki
    Shigemoto, Kazuhiro
    JOURNAL OF NEUROIMMUNOLOGY, 2012, 245 (1-2) : 75 - 78
  • [3] INHIBITORY EFFECT OF KANAMYCIN ON EVOKED TRANSMITTER RELEASE - REVERSAL BY 3,4-DIAMINOPYRIDINE
    MOLGO, J
    LEMEIGNAN, M
    UCHIYAMA, T
    LECHAT, P
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1979, 57 (01) : 93 - 97
  • [4] 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome
    Wirtz, Paul W.
    Titulaer, Maarten J.
    van Gerven, Joop M. A.
    Verschuuren, Jan J.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2010, 6 (06) : 867 - 874
  • [5] Pharmacokinetics and safety of 3,4-diaminopyridine base in healthy Japanese volunteers
    Ishida, Natsuko
    Kobayashi, Erina
    Kondo, Yuya
    Matsushita, Ryo
    Komai, Kiyonobu
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (08) : 674 - 680
  • [6] Antidotal treatment of botulism in rats by continuous infusion with 3,4-diaminopyridine
    Machamer, James B.
    Vazquez-Cintron, Edwin J.
    O'Brien, Sean W.
    Kelly, Kyle E.
    Altvater, Amber C.
    Pagarigan, Kathleen T.
    Dubee, Parker B.
    Ondeck, Celinia A.
    McNutt, Patrick M.
    MOLECULAR MEDICINE, 2022, 28 (01)
  • [7] Antidotal treatment of botulism in rats by continuous infusion with 3,4-diaminopyridine
    James B. Machamer
    Edwin J. Vazquez-Cintron
    Sean W. O’Brien
    Kyle E. Kelly
    Amber C. Altvater
    Kathleen T. Pagarigan
    Parker B. Dubee
    Celinia A. Ondeck
    Patrick M. McNutt
    Molecular Medicine, 2022, 28
  • [8] A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome
    Sanders, DB
    Massey, JM
    Sanders, LL
    Edwards, LJ
    NEUROLOGY, 2000, 54 (03) : 603 - 607
  • [9] Effects of 3,4-diaminopyridine on myasthenia gravis: Preliminary results of an open-label study
    Ceccanti, Marco
    Libonati, Laura
    Ruffolo, Gabriele
    Cifelli, Pierangelo
    Moret, Federica
    Frasca, Vittorio
    Palma, Eleonora
    Inghilleri, Maurizio
    Cambieri, Chiara
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [10] 3,4-Diaminopyridine (amifampridine) for the treatment of Lambert-Eaton myasthenic syndrome
    Lindquist, Sabine
    Stangel, Martin
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (03): : 293 - 300